Quick Answer
enGene Therapeutics Inc. reported Net Income of -$117.30 million for fiscal year 2025.
enGene Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$117.30M -112.7% |
-$55.14M +44.8% |
-$99.92M -308.5% |
-$24.46M | — |
| Diluted EPS | $2.29 +56.8% |
$1.46 -99.0% |
$151.22 +241.4% |
$44.30 | — |
| Total Assets | $221.47M -28.8% |
$311.17M +257.8% |
$86.96M +263.7% |
$23.91M | — |
| Cash and Equivalents | $50.15M -71.0% |
$173.00M +112.2% |
$81.52M +298.9% |
$20.43M | — |
| Stockholders Equity | $167.71M -38.5% |
$272.61M +276.1% |
$72.49M +194.6% |
-$76.61M -43.4% |
-$53.44M |
| R&D Expense | $94.48M +146.6% |
$38.31M +132.8% |
$16.46M +6.4% |
$15.47M | — |
| Operating Income | -$123.17M -97.7% |
-$62.30M -139.1% |
-$26.06M -34.1% |
-$19.43M | — |
| Shares Outstanding | 52.02M +2.0% |
50.98M +119.7% |
23.20M +3384.4% |
665,767 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | January 31, 2026 | -$29.75M | -20.9% | -2.6% |
| Diluted EPS | January 31, 2026 | $0.44 | -8.3% | -22.8% |
| Total Assets | January 31, 2026 | $337.11M | +17.9% | +52.2% |
| Cash and Equivalents | January 31, 2026 | $36.61M | -41.3% | -27.0% |
| Stockholders Equity | January 31, 2026 | $281.55M | +12.6% | +67.9% |
| R&D Expense | January 31, 2026 | $22.25M | +11.4% | -1.4% |
| Operating Income | January 31, 2026 | -$31.18M | -17.2% | -4.1% |
| Shares Outstanding | January 31, 2026 | 66.99M | +31.4% | +28.8% |
- enGene Therapeutics Inc. reported Net Income of -$117.30 million for fiscal year 2025.
- enGene Therapeutics Inc. showed a decrease of -112.7% in Net Income compared to the prior fiscal year.
- enGene Therapeutics Inc. reported Diluted EPS of $2.29 per share for fiscal year 2025.
- enGene Therapeutics Inc. showed an increase of +56.8% in Diluted EPS compared to the prior fiscal year.
- enGene Therapeutics Inc. reported Total Assets of $221.47 million for fiscal year 2025.
- enGene Therapeutics Inc. showed a decrease of -28.8% in Total Assets compared to the prior fiscal year.
- enGene Therapeutics Inc. reported Cash and Equivalents of $50.15 million for fiscal year 2025.
- enGene Therapeutics Inc. showed a decrease of -71.0% in Cash and Equivalents compared to the prior fiscal year.
- enGene Therapeutics Inc. reported Stockholders Equity of $167.71 million for fiscal year 2025.
- enGene Therapeutics Inc. showed a decrease of -38.5% in Stockholders Equity compared to the prior fiscal year.
- enGene Therapeutics Inc. reported R&D Expense of $94.48 million for fiscal year 2025.
- enGene Therapeutics Inc. showed an increase of +146.6% in R&D Expense compared to the prior fiscal year.
- enGene Therapeutics Inc. reported Operating Income of -$123.17 million for fiscal year 2025.
- enGene Therapeutics Inc. showed a decrease of -97.7% in Operating Income compared to the prior fiscal year.
- enGene Therapeutics Inc. reported Shares Outstanding of 52.02 million shares for fiscal year 2025.
- enGene Therapeutics Inc. showed an increase of +2.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: